Clinical trial
Dose Optimization Study of Idelalisib in Follicular Lymphoma
NCT02536300 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dose Optimization Study of Idelalisib in Follicular Lymphoma
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 14, 2016
- Completion date
- September 27, 2022
- Enrollment
- 96 (actual)
- Sites
- 66
Conditions
As the registry lists them; a condition with its own page is linked.
follicular lymphoma